Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NEX-20A (Lenalidomide) in Healthy Males
NCT05643248Phase 1Completed
- Sponsor
- Nanexa AB
- Start
- Nov 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NEX-20A in multiple myeloma (MM) (3 cohorts), sponsored by Nanexa AB. Primary endpoints: Number of subjects with a clinical significant change from baseline in the systolic blood pressure at Day 36, Number of subjects with a clinical significant change from baseline in the diastolic blood pressure at Day 36 and 5 more. Started Nov 2022; status: completed.
02
Drugs
NEX-20A
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05643248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643248.